[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100460596":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":38,"responsibleParty":74,"collaborators":26,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":26,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":26,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":68,"whyStopped":26,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"experimental group","EXPERIMENTAL","concurrent chemotherapy: cisplatin（DDP） weekly, 40mg\u002Fm2, begin with radiation Drug: cisplatin（DDP） weekly; pelvic radiotherapy: intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy\u002Ffraction\u002Fday with total dose summed up to 45-50Gy.",[13],"Drug: adjuvant concurrent chemoradiotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"controlled group","ACTIVE_COMPARATOR","pelvic radiotherapy alone: intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy\u002Ffraction\u002Fday with total dose summed up to 45-50Gy.",[19],"Radiation: radiotherapy",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","adjuvant concurrent chemoradiotherapy","concurrent chemotherapy: cisplatin（DDP） weekly, 40mg\u002Fm2, begin with radiation Drug: cisplatin（DDP） weekly; Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy\u002Ffraction\u002Fday with total dose summed up to 45-50Gy.",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"RADIATION","radiotherapy","Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy\u002Ffraction\u002Fday with total dose summed up to 45-50Gy.",[15],[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Wei-Xiang Qi, Dr.","CONTACT","+862164370045","qiweixiang1113@163.com",[39,67],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Ruijin Hospital, Shanghai jiaotong univestigy school of medicine","NOT_YET_RECRUITING","Shanghai","Shanghai Municipality","200025","China","CN",{"type":48,"coordinates":49},"Point",[50,51],121.45806,31.22222,{"lat":51,"lon":50},[54,56,59,61,63,65],{"name":55,"role":35,"phone":36,"phoneExt":26,"email":26},"Yifeng Wang",{"name":57,"role":58,"phone":26,"phoneExt":26,"email":26},"Rong Cai, Dr.","PRINCIPAL_INVESTIGATOR",{"name":60,"role":58,"phone":26,"phoneExt":26,"email":26},"Haoping Xu, Dr",{"name":62,"role":58,"phone":26,"phoneExt":26,"email":26},"Weiwei Feng, Dr.",{"name":64,"role":58,"phone":26,"phoneExt":26,"email":26},"Yuqing Zhao, Dr.",{"name":66,"role":58,"phone":26,"phoneExt":26,"email":26},"Weiguo Hu, Dr.",{"facility":40,"status":68,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":69,"geoPoint":71,"contacts":72},"RECRUITING",{"type":48,"coordinates":70},[50,51],{"lat":51,"lon":50},[73],{"name":55,"role":35,"phone":36,"phoneExt":26,"email":26},{"type":75,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100460596","phase-3-adjuvant-concurrent-chemoradiotherapy-versus-radiotherapy-in-early-stage-cervical-cancer-patients-100460596",false,"NCT05277688","Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients","Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients With Selected Intermediate-risk Factors: a Randomized Controlled Phase III Trials (ACCEPT Trial)","Inclusion Criteria:\n\n* • 18 Years to 80 Years\n\n  * Histologically proven cervical cancer, FIGO stage Ia2-IIb,and no previous chemotherapy and radiotherapy\n  * Accepted radical hysterectomy 3-4 weeks before\n  * Karnofsky score \\>70\n  * Postoperative pathology with one of the three risk factors criterials: (1) lympho-vascular space invasion(LVSI+) and deep 1\u002F3 stromal invasion; (2 ) LVSI(+) and middle 1\u002F3 stromal invasion, and tumor size≥4cm (3)Non-squamous cell carcinoma;\n  * Examination results showed no radiation or chemotherapy contraindication\n  * Willing to accept treatment\n  * Ability to comply with trial requirements\n\nExclusion Criteria:\n\n* • Postoperative residual\n\n  * Postoperative recurrence or metastasis\n  * Pelvic lymph node metastasis\n  * parametrial invasion\n  * positive surgical margin\n  * Without lymph node dissection\n  * Postoperative pathology showed aortic lymph node metastasis\n  * Examination results showed radiotherapy contraindications\n  * No indications for radiotherapy","FEMALE","18 Years","80 Years",{"count":87,"type":88},340,"ESTIMATED","INTERVENTIONAL",[91],"PHASE3","To evaluate if adjuvant concurrent chemoradiotherapy is associated with a recurrence-free survival benefit in comparison with radiotherapy alone in selected intermediate risk cervical cancer after radical surgery.",[94],"Cervical Cancer",[96,97,98,29,99],"cervical cancer","early stage","chemoradiotherapy","survival","2026-08-17",{"date":102,"type":103},"2026-08-18","ACTUAL",{"date":105,"type":103},"2022-03-15",{"date":107,"type":88},"2027-12-30",{"name":5,"class":6},2]